An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Noguchi, Masanori; Matsumoto, Kazumasa; Uemura, Hirotsugu; Arai, Gaku; Eto, Masatoshi; Naito, Seiji; Οhyama, Chikara; Nasu, Yasutomo; Tanaka, Masatoshi; Moriya, Fukuko; Suekane, Shigetaka; Matsueda, Satoko; Komatsu, Nobukazu; Sasada, Tetsuro; Yamada, Akira; Kakuma, Tatsuyuki; Itoh, Kyogo

doi:10.1158/1078-0432.ccr-15-1265

Cited by 50 publications

(107 citation statements)

References 22 publications

(27 reference statements)

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…Treatment was fairly well tolerated; almost all AEs were of grade 1 or 2; there were no grade 4 AEs or treatment-related deaths. Obviously, as the authors concluded, further large-scale, randomized trials are needed to confirm these results [52]. …”

Section: Other Immunotherapiesmentioning

confidence: 99%

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

Zichi

Tucci

Leone

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

In recent years, immunotherapy has produced encouraging results in a rapidly increasing number of solid tumors. The responsiveness of bladder cancer to immunotherapy was first established in nonmuscle invasive disease in 1976 with intravesical instillations of bacillus Calmette-Guérin (BCG). Very recently immune checkpoint inhibitors demonstrated good activity and significant efficacy in metastatic disease. In particular the best results were obtained with programmed death-ligand-1 (PD-L1) and programmed death-1 (PD-1) inhibitors, but many other immune checkpoint inhibitors, including anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibodies, are currently under investigation in several trials. Simultaneously other therapeutic strategies which recruit an adaptive immune response against tumoral antigens or employ externally manipulated tumor infiltrating lymphocytes might change the natural history of bladder cancer in the near future. This review describes the rationale for the use of immunotherapy in bladder cancer and discusses recent and ongoing clinical trials with checkpoint inhibitors and other novel immunotherapy agents.

show abstract

Section: Other Immunotherapiesmentioning

confidence: 99%

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

Zichi

Tucci

Leone

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…We have used one of the HLA-A24-restricted epitopes, EGFR 800-809 , as a candidate peptide for personalized peptide vaccination, in which vaccine antigens are selected and administered based on the pre-existing host immunity before vaccination (Sasada et al, 2014). Recent clinical trials of personalized peptide vaccination have demonstrated significantly prolonged overall survival in patients with advanced cancers, including prostate and bladder cancer, through induction of antigen-specific T cells (Sasada et al, 2014; Noguchi et al, 2016; Yoshimura et al, 2016). …”

Section: Cellular Immune Responses To Wild Type Egfrmentioning

confidence: 99%

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment

et al. 2016

Self Cite

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is a prototypic cell-surface receptor belonging to the ErbB/HER onocogene family. Overexpression or somatic mutations of EGFR have been reported to play an important role in tumorigenesis in various types of epithelial cancers. Therefore, targeting of EGFR with specific blocking antibodies or inhibitors have been developing for treatment for EGFR-associated tumors. Immune responses to HER2, another molecule of the ErbB/HER onocogene family, have been well studied, but only limited information on the immune responses to EGFR in cancer has been currently available. In this review, we have summarized the available data and discussed potential clinical importance of the anti-EGFR immune responses and EGFR-mediated immune regulation in cancer. Several lines of evidence suggest that cellular and humoral immune responses to EGFR might be useful as a marker and/or target for cancer therapy against EGFR-associated tumors. In addition, recent studies suggest the critical roles of EGFR-mediated signaling in regulation of expression of an immune checkpoint molecule, programmed death-ligand 1 (PD-L1) in tumor cells. Further studies are warranted to clarify the impact of the anti-EGFR immune responses and EGFR-mediated immunomodulation for clinical application for cancer treatment.

show abstract

“…For muscle invasive disease, treatment with a personalized vaccine was recently showed to improve overall survival versus best supportive care [32]. In this study, patients were randomized to best supportive care with or without a personalized vaccine that included 2–4 of 31 candidate peptides selected based on HLA types and peptide-reactive IgG titers.…”

Section: Therapeutic Targeting Of Dysfunctional Anti-tumor Immunitymentioning

confidence: 99%

Emerging role of immunotherapy in urothelial carcinoma—Immunobiology/biomarkers

Sweis

Galsky

2016

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette–Guerin (BCG) was shown to prevent recurrence. Since that time, our knowledge of immune biology of cancer has expanded tremendously, and bladder cancer patients finally have new active immunotherapeutic drugs with on the horizon. Anti-programmed cell death-1 (PD-1)/(programmed cell death ligand-1 (PD-L1) therapy has shown impressively durable responses in urothelial bladder cancer (UBC), but the reported response rates warrant improvement. To outline potential strategies to overcome tumor immune resistance, herein, we summarize current models of tumor immunology with a specific focus on bladder cancer. Recognition of tumor-specific antigens through cross-presentation, T cell priming and activation, and trafficking of immune cells to the tumor microenvironment are some of the critical steps we now understand to be necessary for an effective anti-tumor immune response. Many of the involved steps are important targets for therapeutic interventions. As new immunotherapies are developed, predictive biomarkers will also be important to select patients most likely to respond and to better understand tumor biology. Several potential biomarkers are reviewed including PD-L1 expression, identification of T cell-inflamed/non-T cell-inflamed tumors based on immune gene expression, intrinsic molecular subtyping based on luminal/basal or the cancer genome atlas (TCGA) groups, T cell receptor (TCR) sequencing, and somatic mutational density. Within even the past few years our current knowledge of immune biology has exploded, and we are highly optimistic about the future of UBC therapy that will be available to patients.

show abstract

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Cited by 50 publications

References 22 publications

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment

Emerging role of immunotherapy in urothelial carcinoma—Immunobiology/biomarkers

Contact Info

Product

Resources

About